Department of Medical Sciences, University of Turin, Turin, Italy.
Acta Diabetol. 2021 Jul;58(7):819-830. doi: 10.1007/s00592-020-01656-9. Epub 2021 Feb 2.
Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD). Although both albuminuria and glomerular filtration rate (GFR) are well-established diagnostic/prognostic biomarkers of DKD, they have important limitations. There is, thus, increasing quest to find novel biomarkers to identify the disease in an early stage and to improve risk stratification. In this review, we will outline the major pitfalls of currently available markers, describe promising novel biomarkers, and discuss their potential clinical relevance. In particular, we will focus on the importance of recent advancements in multi-omic technologies in the discovery of new DKD biomarkers. In addition, we will provide an update on new emerging approaches to explore renal function and structure, using functional tests and imaging.
糖尿病肾病(DKD)是终末期肾病(ESRD)的主要原因。虽然蛋白尿和肾小球滤过率(GFR)都是 DKD 的既定诊断/预后生物标志物,但它们存在重要的局限性。因此,人们越来越希望找到新的生物标志物,以便在早期识别疾病并改善风险分层。在这篇综述中,我们将概述当前可用标志物的主要缺陷,描述有前途的新型生物标志物,并讨论它们的潜在临床意义。特别是,我们将重点介绍多组学技术在发现新的 DKD 生物标志物方面的最新进展。此外,我们还将介绍使用功能测试和成像来探索肾功能和结构的新出现方法的最新进展。